According to the Treasure Island announcement, the company's independent directors issued independent opinions on matters relating to the Shanghai Stock Exchange's 2025 annual report regulatory inquiry letter: in addition to the disclosed controlling shareholder's non-operating occupation of the company's capital of 233 million yuan, the controlling shareholder also occupied 66.023,600 yuan of the company's capital in 2022 through Heilongjiang Jinjiu Pharmaceutical Co., Ltd., and up to now, all of the aforementioned occupied funds have been returned; the company's comprehensive self-inspection work has not yet been completed. Related transactions were compliant and pricing was fair during the reporting period. There were no illegal guarantees, undisclosed or contingent liabilities, or other misappropriation of potential benefits in the past three years, prepayment transactions in the current period were regulated, and no additional capital was used.

According to the Treasure Island announcement, the company's independent directors issued independent opinions on matters relating to the Shanghai Stock Exchange's 2025 annual report regulatory inquiry letter: in addition to the disclosed controlling shareholder's non-operating occupation of the company's capital of 233 million yuan, the controlling shareholder also occupied 66.023,600 yuan of the company's capital in 2022 through Heilongjiang Jinjiu Pharmaceutical Co., Ltd., and up to now, all of the aforementioned occupied funds have been returned; the company's comprehensive self-inspection work has not yet been completed. Related transactions were compliant and pricing was fair during the reporting period. There were no illegal guarantees, undisclosed or contingent liabilities, or other misappropriation of potential benefits in the past three years, prepayment transactions in the current period were regulated, and no additional capital was used.